ProKidney Corp.

ProKidney did not report quarterly revenue, EPS, or gross margin on this call. In the Phase II RMCL-002 update, the company said the active group had a cumulative minus 3.2 mL change in average eGFR after 30 months, versus a minus 3.4 mL decline in the deferred group after 12 months on standard of care. In a subgroup of 13 stage 4 CKD patients with severe albuminuria, the active group’s average change from baseline in eGFR was minus 1.6 mL over 12 months, versus minus 6 mL for the standard-of-care group. Management said over 80 subjects have been enrolled in ProACT 1, about 50 of them meet the new inclusion criteria, and approximately 50 patients already enrolled meet the updated protocol requirements. Final Phase II results are expected in the first half of 2024, ProACT 1 enrollment is expected to resume in the first half of 2024, and both Phase III studies are now expected to complete in 2027.

Bruce Culleton framed the strategy as focusing REACT on the highest-risk CKD patients, saying the Phase II data suggest the strongest effect in stage 4 disease with severe albuminuria. He said narrowing ProACT 1 and leaving ProACT 2 unchanged should increase the probability of success, and he noted that the company is also addressing EU manufacturing documentation issues in parallel. His tone was cautiously optimistic: he repeatedly emphasized that the delay is intended to improve the program rather than reflect a clinical safety concern.

James Coulston did not discuss detailed quarterly financial statements on the call, but he said the company is “well capitalized well into 2025” and expects a couple of potential financing catalysts in the interim. Those catalysts were described as upcoming data from the Phase II 007 study in mid-2024 and final 002 results in the first half of 2024. He also reiterated that the manufacturing pause is tied to quality documentation remediation after the EU audit, not to a safety event.

Analysts focused on why narrowing ProACT 1 would delay enrollment if the 20-35 range was already open, what happens to already-enrolled patients outside the new criteria, and whether interim analysis timing has changed. Management said existing patients who do not meet the new criteria will still be followed and included in the final FDA analysis set, and that the delay reflects both protocol changes and the manufacturing pause. On interim timing, they said no decision has been made yet. Other questions covered whether REACT’s effect may wear off and whether redosing could be needed around 18 to 24 months; management said durability is not yet certain from Phase II and that Phase III should provide better insight. Analysts also asked about GLP-1s and the evolving CKD landscape; management said standard of care will be maintained in both arms and declined to speculate until more FLOW data are published.